Exploration on the Improvement of Cognitive Function and Inflammatory Response in Perimenopausal Patients with Mild Cognitive Impairment by Self-Prepared Ningshen Prescription

Table 1

Comparison of general data between the two groups.

Data		Control group (n = 40)	Therapy group (n = 40)	t or χ^2 value	value
Age distribution (n, %)	40∼45 years	9 (22.50)	7 (17.50)	0.825	0.843
	46∼50 years	14 (35.00)	12 (30.00)
	51∼55 years	13 (32.50)	16 (40.00)
	56∼60 years	4 (10.00)	5 (12.50)
Age at menarche (years,  ± s)		15.12 ± 1.37	14.89 ± 1.43	0.735	0.465
Duration of disease (months,  ± s)		4.03 ± 0.91	4.06 ± 0.93	0.146	0.884
Menopause (n, %)		9 (22.50)	7 (17.50)	0.313	0.576
Level of education (n, %)	Illiterate	4 (10.00)	6 (15.00)	1.376	0.711
	Primary school	13 (32.50)	12 (30.00)
	Lower secondary	16 (40.00)	18 (45.00)
	High school and above	7 (17.50)	4 (10.00)
Personal history (n, %)	Smoking	9 (22.50)	11 (27.50)	0.267	0.606
	Alcohol consumption	7 (17.50)	10 (25.00)	0.672	0.412
MocA (points,  ± s)		21.32 ± 1.34	21.51 ± 1.43	0.613	0.542
ADL (points,  ± s)		45.51 ± 8.27	46.27 ± 7.87	0.421	0.675
TCM symptom score (points,  ± s)		16.23 ± 4.10	16.57 ± 4.23	0.365	0.716
hs-CRP (μmol/L,  ± s)		15.87 ± 2.63	15.42 ± 2.66	0.761	0.449
Hcy (μmol/L,  ± s)		14.21 ± 4.69	14.87 ± 4.76	0.625	0.534
IL-1β (ng/L,  ± s)		50.22 ± 13.18	50.46 ± 12.69	0.083	0.934
ALT (U/L,  ± s)		24.23 ± 4.07	23.95 ± 3.89	0.315	0.754
AST (U/L,  ± s)		19.08 ± 3.72	19.14 ± 4.03	0.069	0.945
Cr (μmol/L,  ± s)		80.24 ± 13.15	81.07 ± 13.99	0.273	0.785